nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Androgen receptor as a target in androgen-independent prostate cancer
|
Balk, Steven P |
|
2002 |
60 |
3S1 |
p. 132-138 7 p. |
artikel |
2 |
Antiandrogen monotherapy: indications and results
|
Iversen, Peter |
|
2002 |
60 |
3S1 |
p. 64-71 8 p. |
artikel |
3 |
A review of measurement of patient preferences for treatment outcomes after prostate cancer
|
Lubeck, Deborah P |
|
2002 |
60 |
3S1 |
p. 72-77 6 p. |
artikel |
4 |
Chemotherapy for prostate cancer
|
Gilligan, Timothy |
|
2002 |
60 |
3S1 |
p. 94-100 7 p. |
artikel |
5 |
CME assessment test and evaluation form
|
|
|
2002 |
60 |
3S1 |
p. 141-145 5 p. |
artikel |
6 |
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer
|
Meng, Maxwell V |
|
2002 |
60 |
3S1 |
p. 7-11 5 p. |
artikel |
7 |
Discussion following Dr. Balk’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 138-139 2 p. |
artikel |
8 |
Discussion following Dr. Carroll’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 11-12 2 p. |
artikel |
9 |
Discussion following Dr. D’Amico’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 37-38 2 p. |
artikel |
10 |
Discussion following Dr. George’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 122- 1 p. |
artikel |
11 |
Discussion following Dr. Grossfeld’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 62-63 2 p. |
artikel |
12 |
Discussion following Dr. Johnson’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 130-131 2 p. |
artikel |
13 |
Discussion following Dr. Kantoff’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 100- 1 p. |
artikel |
14 |
Discussion following Dr. Kelly’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 113-114 2 p. |
artikel |
15 |
Discussion following Dr. Klotz’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 51- 1 p. |
artikel |
16 |
Discussion following Dr. Klotz’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 56- 1 p. |
artikel |
17 |
Discussion following Dr. Lee’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 44- 1 p. |
artikel |
18 |
Discussion following Dr. Lubeck’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 77-78 2 p. |
artikel |
19 |
Discussion following Dr. Mcleod’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 21- 1 p. |
artikel |
20 |
Discussion following Dr. Oh’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 93- 1 p. |
artikel |
21 |
Discussion following Dr. Pollack’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 30-31 2 p. |
artikel |
22 |
Discussion following Dr. Sartor’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 107-108 2 p. |
artikel |
23 |
Discussion following Dr. Smith’s presentation
|
|
|
2002 |
60 |
3S1 |
p. 86- 1 p. |
artikel |
24 |
Emerging role of adjuvant hormonal therapy
|
Mcleod, David G |
|
2002 |
60 |
3S1 |
p. 13-20 8 p. |
artikel |
25 |
Endpoints in prostate cancer clinical trials
|
Sartor, Oliver |
|
2002 |
60 |
3S1 |
p. 101-107 7 p. |
artikel |
26 |
Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer
|
Pollack, Alan |
|
2002 |
60 |
3S1 |
p. 22-30 9 p. |
artikel |
27 |
Intermittent androgen suppression in prostate cancer: the Canadian experience
|
Hurtado-Coll, Antonio |
|
2002 |
60 |
3S1 |
p. 52-56 5 p. |
artikel |
28 |
Newer approaches to androgen deprivation therapy in prostate cancer
|
|
|
2002 |
60 |
3S1 |
p. iv-v nvt p. |
artikel |
29 |
Novel trial designs: which agents and how do we test them?
|
Kelly, William Kevin |
|
2002 |
60 |
3S1 |
p. 109-113 5 p. |
artikel |
30 |
Osteoporosis during androgen deprivation therapy for prostate cancer
|
Smith, Matthew R |
|
2002 |
60 |
3S1 |
p. 79-85 7 p. |
artikel |
31 |
Overview consensus statement 1 1 This supplement and conference were funded by an unrestricted educational grant from AstraZeneca Pharmaceuticals. Myles A. Brown is a paid consultant to, and is a study investigator funded by, Novartis Pharmaceuticals. Daniel J. George is a paid consultant to and a member of the speakers’ bureau for Novartis Pharmaceuticals; a paid consultant to TAP Pharmaceuticals; holds stock in and is on the editorial staff for Veritas Medicine; and is a study investigator funded by Wyeth-Ayerst. William Kevin Kelly is a member of the medical advisory board for Amgen Pharmaceuticals and a member of the speakers’ bureau for AstraZeneca Pharmaceuticals and Bristol-Meyers Squibb. Laurence Klotz is a member of the speakers’ bureau for and a paid consultant to AstraZeneca Pharmaceuticals; a paid consultant to Aventis Pharmaceuticals; and a study investigator funded by Abbott Laboratories Canada. W. Robert Lee is a member of the medical advisory board for Nycomed-Amersham. Deborah P. Lubeck is a study investigator funded by TAP Pharmaceuticals. David G. McLeod is a study investigator funded by AstraZeneca Pharmaceuticals. Alan Pollack is a paid consultant to Amgen Pharmaceuticals, AstraZeneca Pharmaceuticals, and TAP Pharmaceuticals. Oliver Sartor is a paid consultant to and a member of the medical advisory board for Atrix Pharmaceuticals. Matthew R. Smith is a study investigator funded by AstraZeneca Pharmaceuticals and is a paid consultant to and a study investigator funded by Novartis Pharmaceuticals.
|
Carroll, Peter R |
|
2002 |
60 |
3S1 |
p. 1-6 6 p. |
artikel |
32 |
Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy
|
Grossfeld, Gary D |
|
2002 |
60 |
3S1 |
p. 57-62 6 p. |
artikel |
33 |
Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the canadian experience
|
Hurtado-coll, Antonio |
|
2002 |
60 |
3S1 |
p. 45-51 7 p. |
artikel |
34 |
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
|
D’Amico, Anthony V. |
|
2002 |
60 |
3S1 |
p. 32-37 6 p. |
artikel |
35 |
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate
|
George, Daniel J |
|
2002 |
60 |
3S1 |
p. 115-121 7 p. |
artikel |
36 |
Secondary hormonal therapies in the treatment of prostate cancer
|
OH, William K |
|
2002 |
60 |
3S1 |
p. 87-92 6 p. |
artikel |
37 |
The role of androgen deprivation therapy combined with prostate brachytherapy
|
Lee, W.Robert |
|
2002 |
60 |
3S1 |
p. 39-44 6 p. |
artikel |
38 |
Vitamin d receptor: a potential target for intervention
|
Johnson, Candace S |
|
2002 |
60 |
3S1 |
p. 123-130 8 p. |
artikel |